Bicycle Therapeutics plc
NASDAQ Global SelectTotal Valuation
Bicycle Therapeutics plc carries a market capitalization of 298.40M, placing it among publicly traded companies globally. Its enterprise value stands at -199.38M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 298.40M |
| Enterprise Value | -199.38M |
Share Statistics
Bicycle Therapeutics plc currently has 69.81M shares outstanding.
| Shares Outstanding | 69.81M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 4.82, and the price-to-book ratio stands at 0.58.
| PE Ratio | N/A |
| PS Ratio | 4.82 |
| PB Ratio | 0.58 |
| P/TBV Ratio | 0.58 |
| P/FCF Ratio | -1.45 |
| P/OCF Ratio | -1.43 |
Financial Position
Bicycle Therapeutics plc maintains a current ratio of 12.08, meaning it holds 12.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.87, indicating elevated leverage, while an interest coverage ratio of -1,063.70 demonstrates limited ability to service its debt obligations.
| Current Ratio | 12.08 |
| Quick Ratio | 11.70 |
| Debt / Equity | 2.87 |
| Debt / EBITDA | -0.07 |
| Interest Coverage | -1,063.70 |
Financial Efficiency
| Return on Equity (ROE) | -32.30 |
| Return on Assets (ROA) | -26.47 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 1.73M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Bicycle Therapeutics plc's stock has declined approximately -38.57143% over the past 52 weeks. The 50-day moving average sits at 4.15, while the 200-day moving average is 5.19.
| Beta (5Y) | N/A |
| 52-Week Price Change | -38.57143% |
| 50-Day Moving Average | 4.15 |
| 200-Day Moving Average | 5.19 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Bicycle Therapeutics plc generated 61.21M in revenue and converted that into -190.41M in net income, yielding earnings per share of -2.74. EBITDA reached -205.29M, while operating income came in at -210.58M.
| Revenue | 61.21M |
| Gross Profit | N/A |
| Operating Income | -210.58M |
| Pretax Income | -188.68M |
| Net Income | -190.41M |
| EBITDA | -205.29M |
| EBIT | -210.58M |
| Earnings Per Share (EPS) | -2.74 |
Balance Sheet
Bicycle Therapeutics plc holds 510.05M in cash and equivalents against 14.66M in total debt, resulting in a net debt position of -510.05M. Total book value stands at 510.26M, with working capital of 527.60M providing operational flexibility.
| Cash & Cash Equivalents | 510.05M |
| Total Debt | 14.66M |
| Net Debt | -510.05M |
| Equity (Book Value) | 510.26M |
| Book Value Per Share | 7.31 |
| Working Capital | 527.60M |
Cash Flow
Bicycle Therapeutics plc produced -206.05M in operating cash flow over the past twelve months. After subtracting -2.23M in capital expenditures, free cash flow totaled -208.28M - equivalent to -3.00 per share.
| Operating Cash Flow | -206.05M |
| Capital Expenditures | -2.23M |
| Free Cash Flow | -208.28M |
| FCF Per Share | -3.00 |
Margins
Bicycle Therapeutics plc operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -344.06 and net profit margin of -311.11 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -344.06 |
| Pretax Margin | -308.28 |
| Profit Margin | -311.11 |
| EBITDA Margin | -335.42 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.05 |
| FCF Yield | -69.13 |
Scores
Bicycle Therapeutics plc posts an Altman Z-Score of -0.49, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.49 |